Yellow fever: A reemerging threat

Clinics in Laboratory Medicine

Volumn 30, Issue 1, 2010, Pages 237-260

  Gardner, Christina L ^a   Ryman, Kate D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Emerging disease; Mosquito borne; Transmission; Vaccine; Yellow fever virus

Indexed keywords

ALPHA INTERFERON; CHIMERIVAX; FLAVIVIRUS VACCINE; LIVE VACCINE; RIBAVIRIN; SMALLPOX VACCINE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASOACTIVE AGENT; VIRUS PROTEIN; VIRUS VACCINE; YELLOW FEVER VACCINE;

ABDOMINAL DISEASE; AEDES AEGYPTI; ARTIFICIAL VENTILATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG INDUCED HEADACHE; ENCEPHALITIS; EPIDEMIC; FLUID RESUSCITATION; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFECTION CONTROL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LABORATORY DIAGNOSIS; LABORATORY TEST; MALAISE; MASS IMMUNIZATION; MICROBIAL ACTIVITY; MYALGIA; NEUROTOXICITY; NONHUMAN; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SMALLPOX; SYMPTOM; URBAN AREA; VACCINE PRODUCTION; VIRION; VIRUS CELL INTERACTION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS; ZOONOSIS;

AEDES; ANIMALS; HUMANS; INSECT VECTORS; VIRUS REPLICATION; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS;

EID: 77953349428     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.01.001     Document Type: Review

References (122)

1. Barrett A.D., Monath T.P. Epidemiology and ecology of yellow fever virus. Adv Virus Res 2003, 61:291-315.
2. Carter H.R. Yellow fever: an epidemiological and historical study of its place of origin 1931, Williams & Wilkins, Baltimore (MD).
3. Tomlinson W., Hodgson R.S. Centennial year of yellow fever eradication in New Orleans and the United States, 1905-2005. La State Med Soc 2005, 157(2):216-217.
4. Staples J.E., Monath T.P. Yellow fever: 100 years of discovery. JAMA 2008, 300(8):960-962.
5. Smith H.H., Theiler M. The adaptation of unmodified strains of yellow fever virus to cultivation in vitro. J Exp Med 1937, 65(6):801-808.
6. Theiler M., Smith H.H. The effect of prolonged cultivation in vitro upon the pathogenicity of yellow fever virus. J Exp Med 1937, 65(6):767-786.
7. Theiler M., Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 1937, 65(6):787-800.
8. Gould E.A., Solomon T. Pathogenic flaviviruses. Lancet 2008, 371(9611):500-509.
9. Chambers T.J., McCourt D.W., Rice C.M. Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera. Virology 1990, 177(1):159-174.
10. Burke D.S., Monath T.P. Flaviviruses. Fields virology 2001, 1043-1125. Lippincott, Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
11. Rice C.M., Lenches E.M., Eddy S.R., et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 1985, 229(4715):726-733.
12. Brinton M.A., Fernandez A.V., Dispoto J.H. The 3'-nucleotides of flavivirus genomic RNA form a conserved secondary structure. Virology 1986, 153(1):113-121.
13. Fernandez-Garcia M.D., Mazzon M., Jacobs M., et al. Pathogenesis of flavivirus infections: using and abusing the host cell. Cell Host Microbe 2009, 5(4):318-328.
14. Bressanelli S., Stiasny K., Allison S.L., et al. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 2004, 23(4):728-738.
15. Modis Y., Ogata S., Clements D., et al. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004, 427(6972):313-319.
16. Brinton M.A., Dispoto J.H. Sequence and secondary structure analysis of the 5'-terminal region of flavivirus genome RNA. Virology 1988, 162(2):290-299.
17. Edgil D., Polacek C., Harris E. Dengue virus utilizes a novel strategy for translation initiation when cap-dependent translation is inhibited. J Virol 2006, 80(6):2976-2986.
18. Lindenbach B.D., Rice C.M. Molecular biology of flaviviruses. Adv Virus Res 2003, 59:23-61.
19. Westaway E.G. Flavivirus replication strategy. Adv Virus Res 1987, 33:45-90.
20. Schlesinger J.J., Brandriss M.W., Putnak J.R., et al. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. J Gen Virol 1990, 71:593-599.
21. Lee J.M., Crooks A.J., Stephenson J.R. The synthesis and maturation of a non-structural extracellular antigen from tick-borne encephalitis virus and its relationship to the intracellular NS1 protein. J Gen Virol 1989, 70(Pt 2):335-343.
22. Mason P.W. Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells. Virology 1989, 169:354-364.
23. Winkler G., Randolph V.B., Cleaves G.R., et al. Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer. Virology 1988, 162(1):187-196.
24. Chung K.M., Liszewski M.K., Nybakken G., et al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A 2006, 103(50):19111-19116.
25. Bray M., Zhao B.T., Markoff L., et al. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J Virol 1989, 63(6):2853-2856.
26. Zhang Y.M., Hayes E.P., McCarty T.C., et al. Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis. J Virol 1988, 62(8):3027-3031.
27. Chung K.M., Nybakken G.E., Thompson B.S., et al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 2006, 80(3):1340-1351.
28. Chung K.M., Thompson B.S., Fremont D.H., et al. Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 2007, 81(17):9551-9555.
29. Arias C.F., Preugschat F., Strauss J.H. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology 1993, 193(2):888-899.
30. 2+-dependent and require a functional Walker B motif in the helicase catalytic core. Virology 2004, 328(2):208-218.
31. Chambers T.J., Grakoui A., Rice C.M. Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J Virol 1991, 65(11):6042-6050.
32. Chambers T.J., Weir R.C., Grakoui A., et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci U S A 1990, 87(22):8898-8902.
33. Falgout B., Pethel M., Zhang Y.M., et al. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol 1991, 65(5):2467-2475.
34. Zhang L., Mohan P.M., Padmanabhan R. Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. J Virol 1992, 66:7549-7554.
35. Li H., Clum S., You S., et al. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids. J Virol 1999, 73(4):3108-3116.
36. Nestorowicz A., Chambers T.J., Rice C.M. Mutagenesis of the yellow fever virus NS2A/2B cleavage site: effects on proteolytic processing, viral replication, and evidence for alternative processing of the NS2A protein. Virology 1994, 199(1):114-123.
37. Warrener P., Tamura J.K., Collett M.S. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J Virol 1993, 67(2):989-996.
38. Egloff M.P., Benarroch D., Selisko B., et al. An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J 2002, 21(11):2757-2768.
39. Issur M., Geiss B.J., Bougie I., et al. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. RNA 2009, 15(12):2340-2350.
40. Ray D., Shah A., Tilgner M., et al. West Nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5. J Virol 2006, 80(17):8362-8370.
41. Chu P.W., Westaway E.G. Characterization of Kunjin virus RNA-dependent RNA polymerase: reinitiation of synthesis in vitro. Virology 1987, 157(2):330-337.
42. Grun J.B., Brinton M.A. Characterization of West Nile virus RNA-dependent RNA polymerase and cellular terminal adenylyl and uridylyl transferases in cell-free extracts. J Virol 1986, 60(3):1113-1124.
43. Guyatt K.J., Westaway E.G., Khromykh A.A. Expression and purification of enzymatically active recombinant RNA-dependent RNA polymerase (NS5) of the flavivirus Kunjin. J Virol Methods 2001, 92(1):37-44.
44. Miller S., Krijnse-Locker J. Modification of intracellular membrane structures for virus replication. Nat Rev Microbiol 2008, 6(5):363-374.
45. Mackenzie J.M., Jones M.K., Young P.R. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 1996, 220:232-240.
46. Mackenzie J.M., Jones M.K., Westaway E.G. Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. J Virol 1999, 73:9555-9567.
47. Welsch S., Miller S., Romero-Brey I., et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 2009, 5(4):365-375.
48. Westaway E.G., Mackenzie J.M., Kenney M.T., et al. Ultrastructure of Kunjin virus-infected cells: colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3, in virus-induced membrane structures. J Virol 1997, 71(9):6650-6661.
49. Roosendaal J., Westaway E.G., Khromykh A., et al. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. J Virol 2006, 80(9):4623-4632.
50. Mackenzie J.M., Kenney MT., Westaway E.G., et al. West Nile virus strain Kunjin NS5 polymerase is a phosphoprotein localized at the cytoplasmic site of viral RNA synthesis. J Gen Virol 2007, 88:1163-1168.
51. Hoenen A., Liu W., Kochs G., et al. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein. J Gen Virol 2007, 88(Pt 11):3013-3017.
52. Lorenz I.C., Kartenbeck J., Mezzacasa A., et al. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J Virol 2003, 77(7):4370-4382.
53. Mackenzie J.M., Westaway E.G. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001, 75(22):10787-10799.
54. Hase T., Summers P.L., Eckels K.H., et al. An electron and immunoelectron microscopic study of dengue-2 virus infection of cultured mosquito cells: maturation events. Arch Virol 1987, 92:273-279.
55. Guirakhoo F., Heinz F.X., Mandl C.W., et al. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol 1991, 72(Pt 6):1323-1329.
56. Yu I.M., Zhang W., Holdaway H.A., et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008, 319:1834-1837.
57. Li L., Lok S.M., Yu I.M., et al. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 2008, 319(5871):1830-1834.
58. Rosen L. Med Trop (Mars) 1981, 41(1):23-29. [in French].
59. Rosen L. Overwintering mechanisms of mosquito-borne arboviruses in temperate climates. Am J Trop Med Hyg 1987, 37(Suppl 3):69S-76S.
60. Monath T.P. Facing up to re-emergence of urban yellow fever. Lancet 1999, 353(9164):1541.
61. Bres P.L. A century of progress in combating yellow fever. Bull World Health Organ 1986, 64(6):775-786.
62. Monath T.P. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull Soc Pathol Exot 2006, 99(5):341-347.
63. Monath T.P. Yellow fever: an update. Lancet Infect Dis 2001, 1(1):11-20.
64. Brunette G.W., Kozarsky P.E., Magill A.J., et al. CDC health information for international travel 2010 2009, Elsevier, [Online].
65. Briand S., Beresniak A., Nguyen T., et al. Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach. PLoS Negl Trop Dis 2009, 3:e483.
66. Onyango C.O., Ofula V.O., Sang R.C., et al. Yellow fever outbreak, Imatong, southern Sudan. Emerg Infect Dis 2004, 10(6):1063-1068.
67. Robertson S.E., Hull B.P., Tomori O., et al. Yellow fever: a decade of reemergence. JAMA 1996, 276(14):1157-1162.
68. Bryant J.E., Holmes E.C., Barrett A.D. Out of Africa: a molecular perspective on the introduction of yellow fever virus into the Americas. PLoS Pathog 2007, 3(5):e75.
69. World Health Organisation Yellow fever vaccine. WHO position paper. Wkly Epidemiol Rec 2003, 78(40):349-359.
70. Monath T.P. Yellow fever: Victor, Victoria? Conqueror, conquest? Epidemics and research in the last forty years and prospects for the future. Am J Trop Med Hyg 1991, 45(1):1-43.
71. Nasidi A., Monath T.P., DeCock K., et al. Urban yellow fever epidemic in western Nigeria 1987. Trans R Soc Trop Med Hyg 1989, 83:401-406.
72. Barrett A.D., Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007, 52:209-229.
73. Monath T.P., Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis 2002, 34(10):1369-1378.
74. Monath T.P. Treatment of yellow fever. Antiviral Res 2008, 78(1):116-124.
75. Klotz O., Belt T.H. The pathology of the liver in yellow fever. Am J Pathol 1930, 6:663-688.
76. De Brito T., Siqueira S.A., Santos R.T., et al. Human fatal yellow fever. Immunohistochemical detection of viral antigens in the liver, kidney and heart. Pathol Res Pract 1992, 188(1-2):177-181.
77. Quaresma J.A., Barros V.L., Pagliari C., et al. Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology 2006, 345(1):22-30.
78. ter Meulen J., Sakho M., Koulemou K., et al. Activation of the cytokine network and unfavorable outcome in patients with yellow fever. J Infect Dis 2004, 190(10):1821-1827.
79. Khaiboullina S.F., Rizvanov A.A., Holbrook M.R., et al. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 2005, 342(2):167-176.
80. Monath T.P., Barrett A.D. Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 2003, 60:343-395.
81. Monath T.P. Yellow fever: a medically neglected disease. Report on a seminar. Rev Infect Dis 1987, 9(1):165-175.
82. Huggins J.W., Hsiang C.M., Cosgriff T.M., et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991, 164(6):1119-1127.
83. Arroyo J.I., Apperson S.A., Cropp C.B., et al. Effect of human gamma interferon on yellow fever virus infection. Am J Trop Med Hyg 1988, 38(3):647-650.
84. Barrett A.D. Yellow fever vaccines. Biologicals 1997, 25(1):17-25.
85. Monath T.P. Yellow fever vaccine. Expert Rev Vaccines 2005, 4(4):553-574.
86. Monath T.P., Cetron M.S., McCarthy K., et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005, 1(5):207-214.
87. Reinhardt B., Jaspert R., Niedrig M., et al. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998, 56(2):159-167.
88. Niedrig M., Lademann M., Emmerich P., et al. Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA. Trop Med Int Health 1999, 4(12):867-871.
89. Poland J.D., Calisher C.H., Monath T.P., et al. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 1981, 59(6):895-900.
90. Palmer D.R., Fernandez S., Bisbing J., et al. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 2007, 88(Pt 1):148-156.
91. Querec T., Bennouna S., Alkan S., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203:413-424.
92. Barba-Spaeth G., Longman R.S., Albert M.L., et al. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 2005, 202(9):1179-1184.
93. Hacker U.T., Erhardt S., Tschöp K., et al. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination. Clin Exp Immunol 2001, 125:465-469.
94. Hacker U.T., Jelinek T., Erhardt S., et al. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis 1998, 177(3):774-778.
95. Bonnevie-Nielsen V., Heron I., Monath T.P., et al. Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol 1995, 2(3):302-306.
96. Roers A., Hochkeppel H.K., Horisberger M.A., et al. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994, 169(4):807-813.
97. Co M.D., Terajima M., Cruz J., et al. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 2002, 293(1):151-163.
98. van der Most R.G., Harrington L.E., Giuggio V., et al. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 2002, 296(1):117-124.
99. Hahn C.S., Dalrymple J.M., Strauss J.H., et al. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc Natl Acad Sci U S A 1987, 84(7):2019-2023.
100. Wang E., Ryman K.D., Jennings A.D., et al. Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol 1995, 76(Pt 11):2749-2755.
101. Xie H., Ryman K.D., Campbell G.A., et al. Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus. J Gen Virol 1998, 79(Pt 8):1895-1899.
102. dos Santos C.N., Post P.R., Carvalho R., et al. Complete nucleotide sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus Res 1995, 35(1):35-41.
103. Galler R., Post P.R., Santos C.N., et al. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998, 16(9-10):1024-1028.
104. Ryman K.D., Ledger T.N., Campbell G.A., et al. Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology 1998, 244(1):59-65.
105. Ryman K.D., Xie H., Ledger T.N., et al. Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology 1997, 230(2):376-380.
106. Dunster L.M., Wang H., Ryman K.D., et al. Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology 1999, 261(2):309-318.
107. McArthur M.A., Suderman M.T., Mutebi J.P., et al. Molecular characterization of a hamster viscerotropic strain of yellow fever virus. J Virol 2003, 77(2):1462-1468.
108. Fatal viral encephalitis following 17D yellow fever vaccine inoculation. Report of a case in a 3-year-old child. JAMA 1966, 198(6):671-672.
109. Merlo C., Steffen R., Landis T., et al. Possible association of encephalitis and 17D yellow fever vaccination in a 29-year-old traveller. Vaccine 1993, 11(6):691.
110. Schoub B.D., Dommann C.J., Johnson S., et al. Encephalitis in a 13-year-old boy following 17D yellow fever vaccine. J Infect 1990, 21(1):105-106.
111. Centers for Disease Control and Prevention (CDC) Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. MMWR Morb Mortal Wkly Rep 2002, 51(44):989-993.
112. From the Centers for Disease Control and Prevention Adverse events associated with 17D-derived yellow fever vaccination-United States, 2001-2002. JAMA 2002, 288(20):2533-2535.
113. Belsher J.L., Gay P., Brinton M., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25(50):8480-8485.
114. Chan R.C., Penney D.J., Little D., et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358(9276):121-122.
115. Gerasimon G., Lowry K. Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 2005, 98(6):653-656.
116. Martin M., Tsai T.F., Cropp B., et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358(9276):98-104.
117. Vasconcelos P.F., Luna E.J., Galler R., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(9276):91-97.
118. Struchiner C.J., Luz P.M., Dourado I., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004, 132(5):939-946.
119. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101(10):967-971.
120. Global Advisory Committee on Vaccine Safety, 12-13 December 2007. Wkly Epidemiol Rec 2008, 83(4):37-44.
121. WHO Requirements for yellow fever vaccine. World Health Organ Tech Rep Ser 1998, 872(Annex 2):30-68.
122. Pugachev K.V., Guirakhoo F., Monath T.P. New developments in flavivirus vaccines with special attention to yellow fever. Curr Opin Infect Dis 2005, 18(5):387-394.